JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB313102

Alexa Fluor® 568 Anti-Choline Acetyltransferase antibody [EPR16590]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Choline Acetyltransferase antibody - conjugated to Alexa Fluor® 568. Suitable for Target Binding Affinity, Antibody Labelling, IHC-P and reacts with Mouse, Rat samples.

View Alternative Names

Choline O-acetyltransferase, CHOACTase, ChAT, Choline acetylase, CHAT

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Choline Acetyltransferase antibody [EPR16590]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Choline Acetyltransferase antibody [EPR16590]

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Choline Acetyltransferase antibody [EPR16590]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Choline Acetyltransferase antibody [EPR16590]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Choline Acetyltransferase antibody [EPR16590]

  • Unconjugated

    Anti-Choline Acetyltransferase antibody [EPR16590]

  • Carrier free

    Anti-Choline Acetyltransferase antibody [EPR16590] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR16590

Isotype

IgG

Conjugation

Alexa Fluor® 568

Excitation/Emission

Ex: 578nm, Em: 603nm

Carrier free

No

Reacts with

Mouse, Rat

Applications

IHC-P, Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "TargetBindingAffinity" : {"fullname" : "Target Binding Affinity", "shortname":"Target Binding Affinity"}, "AntibodyLabelling" : {"fullname" : "Antibody Labelling", "shortname":"Antibody Labelling"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "TargetBindingAffinity-species-checked": "guaranteed", "TargetBindingAffinity-species-dilution-info": "", "TargetBindingAffinity-species-notes": "", "AntibodyLabelling-species-checked": "guaranteed", "AntibodyLabelling-species-dilution-info": "", "AntibodyLabelling-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" }, "Rat": { "TargetBindingAffinity-species-checked": "guaranteed", "TargetBindingAffinity-species-dilution-info": "", "TargetBindingAffinity-species-notes": "", "AntibodyLabelling-species-checked": "guaranteed", "AntibodyLabelling-species-dilution-info": "", "AntibodyLabelling-species-notes": "", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Choline Acetyltransferase (ChAT) also known as EC 2.3.1.6 acts as the enzyme responsible for synthesizing the neurotransmitter acetylcholine. It catalyzes the transfer of an acetyl group from acetyl-CoA to choline to form acetylcholine. ChAT is a protein with an approximate mass of 70 kDa and is expressed in cholinergic neurons throughout the central and peripheral nervous systems. High expression is observed in regions such as the basal forebrain and neuromuscular junctions which are important for cholinergic signaling.
Biological function summary

The enzyme plays an important role in cholinergic conduction by producing acetylcholine which functions in synaptic transmission. It does not function as part of a larger complex but its activity directly influences cholinergic synapses. Choline acetyltransferase function ensures the synthesis and availability of acetylcholine for release into the synaptic cleft initiating muscle contraction and modulating activity in the central nervous system.

Pathways

Choline acetyltransferase is critical in pathways governing neurotransmitter release such as the cholinergic synapse pathway. It interacts functionally with other proteins within this pathway including acetylcholinesterase which breaks down acetylcholine in the synaptic cleft. This interaction ensures proper neurotransmitter regulation and recycling maintaining synapse function and communication within neuronal circuits.

Alterations in choline acetyltransferase activity relate to neurological disorders including Alzheimer's disease and myasthenia gravis. In Alzheimer's disease reduced choline acetyltransferase function leads to decreased acetylcholine synthesis contributing to the cognitive decline observed in patients. In myasthenia gravis acetylcholine receptors are impaired but effective choline acetyltransferase activity is still necessary to manage neurotransmitter levels. A potential therapeutic angle involves targeting related proteins that exacerbate these conditions to support acetylcholine levels.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses.
See full target information CHAT

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com